Yarrow Bioscience, Inc. (YARW) stock
YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30102% above fair value
$14.35+0.14 (+0.99%)
Close on Nov 18, 2026Market cap $38.31MP/E –Yield –
Yarrow Bioscience operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Yarrow Bioscience's operating cash flow for the twelve months ending Jun 30, 2025 was -$39.77M. For fiscal 2025 it was -$33.12M. The highest annual figure on record is -$2.27M in fiscal 2016.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$33.12M | – |
| FY2024 | Dec 31, 2024 | -$33.97M | – |
| FY2023 | Dec 31, 2023 | -$25.34M | – |
| FY2022 | Dec 31, 2022 | -$29.20M | – |
| FY2021 | Dec 31, 2021 | -$56.37M | – |
| FY2020 | Dec 31, 2020 | -$137.08M | – |
| FY2019 | Dec 31, 2019 | -$73.39M | – |
| FY2018 | Dec 31, 2018 | -$68.66M | – |
| FY2017 | Dec 31, 2017 | -$28.22M | – |
| FY2016 | Dec 31, 2016 | -$2.27M | – |
| FY2015 | Dec 31, 2015 | -$4.18M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.99M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.08M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.80M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.46M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.00M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.48M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.98M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.57M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.48M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.81M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.13M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.23M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.04M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.02M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.54M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.26M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.55M | – |
| Q4 FY2020 | Dec 31, 2020 | -$25.38M | – |
| Q3 FY2020 | Sep 30, 2020 | -$23.64M | – |
| Q2 FY2020 | Jun 30, 2020 | -$35.86M | – |
| Q1 FY2020 | Mar 31, 2020 | -$52.21M | – |
| Q4 FY2019 | Dec 31, 2019 | -$22.25M | – |
| Q3 FY2019 | Sep 30, 2019 | -$21.79M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.72M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.64M | – |
| Q4 FY2018 | Dec 31, 2018 | -$32.55M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.17M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.74M | -34537.8% |
| Q1 FY2018 | Mar 31, 2018 | -$11.20M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.16M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.52M | – |
| Q2 FY2017 | Jun 30, 2017 | $37.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.58M | – |
See a number that looks wrong?